Diana Groza

658 total citations
15 papers, 585 citations indexed

About

Diana Groza is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Diana Groza has authored 15 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Diana Groza's work include Lung Cancer Treatments and Mutations (4 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Metal complexes synthesis and properties (3 papers). Diana Groza is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Metal complexes synthesis and properties (3 papers). Diana Groza collaborates with scholars based in Austria, Italy and Slovakia. Diana Groza's co-authors include Petra Heffeter, Walter Berger, Bernhard K. Keppler, Christian R. Kowol, Gunda Koellensperger, Alexander Roller, Josef Mayr, Kushtrim Kryeziu, Verena Pichler and Gerrit Hermann and has published in prestigious journals such as Angewandte Chemie International Edition, Chemical Communications and Chemical Science.

In The Last Decade

Diana Groza

15 papers receiving 578 citations

Peers

Countries citing papers authored by Diana Groza

Since Specialization

Citations

This map shows the geographic impact of Diana Groza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Groza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Groza more than expected).

Fields of papers citing papers by Diana Groza

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Groza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Groza. The network helps show where Diana Groza may publish in the future.

Co-authorship network of co-authors of Diana Groza

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Groza. A scholar is included among the top collaborators of Diana Groza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Groza. Diana Groza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo 2023 ·Cancer Letters ·(unknown), (unknown), Diana Groza, Hemma Schueffl, Alessio Terenzi, Alexander Tolios, Thomas Mohr, (unknown), Kushtrim Kryeziu, (unknown), Christine Pirker, Bernhard K. Keppler, Walter Berger, Christian R. Kowol, Petra Heffeter	8
2	Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo 2021 ·Chemical Science ·Hemma Schueffl, Sarah Theiner, Gerrit Hermann, Josef Mayr, (unknown), Diana Groza, (unknown), (unknown), (unknown), Arno Schintlmeister, Siegfried Reipert, Michael Wagner, Robert M. Mader, Gunda Koellensperger, Bernhard K. Keppler, Walter Berger, Christian R. Kowol, Anton A. Legin, Petra Heffeter	34
3	Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis 2019 ·European Journal of Cancer ·Diana Groza, (unknown), Carina Dinhof, (unknown), Christine Pirker, Hemma Schueffl, Manfred Ogris, (unknown), Bernhard K. Keppler, (unknown), Christian R. Kowol, W. Berger, Petra Heffeter	2
4	Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074 2018 ·Cells ·Bernhard Englinger, (unknown), (unknown), (unknown), (unknown), (unknown), Diana Groza, Christian R. Kowol, Petra Heffeter, Michael Grusch, Walter Berger	10
5	Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis 2018 ·OncoImmunology ·Diana Groza, (unknown), Pavol Kudela, Martin Holcmann, Christine Pirker, Carina Dinhof, Hemma Schueffl, (unknown), (unknown), (unknown), Michael Grusch, Manfred Ogris, Werner Lubitz, Bernhard K. Keppler, (unknown), Christian R. Kowol, Maria Sibilia, Walter Berger, Petra Heffeter	49
6	Quantum Dot Based Luminescent Nanoprobes for Sigma-2 Receptor Imaging 2017 ·Molecular Pharmaceutics ·(unknown), Elisabetta Fanizza, Sonja Hager, Diana Groza, Petra Heffeter, (unknown), Valentino Laquintana, Maria Lucia Curri, Nicoletta Depalo, Carmen Abate, Nunzio Denora	13
7	Long-term exposure of immortalized keratinocytes to arsenic induces EMT, impairs differentiation in organotypic skin models and mimics aspects of human skin derangements 2017 ·Archives of Toxicology ·(unknown), Kushtrim Kryeziu, (unknown), (unknown), (unknown), Diana Groza, (unknown), Markus Schosserer, (unknown), (unknown), Michael Mildner, Erwin Tschachler, Michael Grusch, Johannes Grillari, Petra Heffeter	29
8	Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: Proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1 2016 ·Pharmacological Research ·(unknown), Diana Groza, Chiara Riganti, Joanna Kopecka, Mauro Niso, Francesco Berardi, Sonja Hager, Petra Heffeter, Miwa Hirai, Hitoshi Tsugawa, Yasuaki Kabe, Makoto Suematsu, Carmen Abate	39
9	An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo 2016 ·Chemical Science ·Josef Mayr, Petra Heffeter, Diana Groza, (unknown), Gunda Koellensperger, Alexander Roller, (unknown), (unknown), Walter Berger, Christian R. Kowol, Bernhard K. Keppler	118
10	Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation 2016 ·Metallomics ·(unknown), Verena Pichler, Petra Heffeter, Buck Hanson, Sarah Theiner, Irene Lichtscheidl, Christoph Kornauth, (unknown), (unknown), Diana Groza, David Berry, Walter Berger, M. Galanski, Michael A. Jakupec, Bernhard K. Keppler	40
11	Targeting a Targeted Drug: An Approach Toward Hypoxia‐Activatable Tyrosine Kinase Inhibitor Prodrugs 2016 ·ChemMedChem ·(unknown), Diana Groza, (unknown), Alessio Terenzi, (unknown), (unknown), Dina Baier, Walter Berger, Petra Heffeter, Christian R. Kowol, Bernhard K. Keppler	22
12	Tumor‐Targeting of EGFR Inhibitors by Hypoxia‐Mediated Activation 2014 ·Angewandte Chemie International Edition ·(unknown), Diana Groza, Kushtrim Kryeziu, Verena Pichler, Alexander Roller, Walter Berger, Petra Heffeter, Christian R. Kowol	61
13	Tumorspezifische, Hypoxie‐basierte Aktivierung von EGFR‐Inhibitoren 2014 ·Angewandte Chemie ·(unknown), Diana Groza, Kushtrim Kryeziu, Verena Pichler, Alexander Roller, Walter Berger, Petra Heffeter, Christian R. Kowol	8
14	The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo 2013 ·European Journal of Cancer ·Petra Heffeter, (unknown), Kushtrim Kryeziu, Diana Groza, Gunda Koellensperger, Wilfried Körner, Ute Jungwirth, Thomas Mohr, Bernhard K. Keppler, Walter Berger	73
15	Maleimide-functionalised platinum(iv) complexes as a synthetic platform for targeted drug delivery 2013 ·Chemical Communications ·Verena Pichler, Josef Mayr, Petra Heffeter, Orsolya Dömötör, Éva A. Enyedy, Gerrit Hermann, Diana Groza, Gunda Köllensperger, (unknown), Walter Berger, Bernhard K. Keppler, Christian R. Kowol	79

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact